Results 61 to 70 of about 35,587 (246)

Mutant IDH1: An immunotherapeutic target in tumors [PDF]

OncoImmunology, 2014
The discovery of driver mutations in cancers has raised interest in their suitability as immunotherapeutic targets. A recent study demonstrates that a point mutation in isocitrate dehydrogenase 1 (IDH1R132H), expressed in gliomas and other tumors, is presented on human MHC class II and induces a mutation-specific CD4+ antitumor T cell response in ...
Theresa, Schumacher, Lukas, Bunse, Wolfgang, Wick, Michael, Platten   +3 more
openaire   +2 more sources

Establishment and molecular profiling of a PDX model of a metachronous brain tumor in a patient with constitutional mismatch repair deficiency with biallelic MSH6 variant

Animal Models and Experimental Medicine, EarlyView.
A 6½‐year‐old girl was diagnosed with a medulloblastoma, SHH activated, subtype 3 and TP53 mutant (somatic). After surgery and chemotherapy, she was monitored with quarterly magnetic resonance imaging (MRI) scans and remained free of disease for almost 4 years.
Daniel Antunes Moreno, Bruna Minniti Mançano, Mirella Baroni, Eric Allison Philot, Felipe Antonio de Oliveira Garcia, Murilo Bonatelli, Flávia Escremim de Paula, Iara Viana Vidigal Santana, Gustavo Ramos Teixeira, Mauricio Yamanari, Luciane Sussuchi da Silva, André Escremim de Paula, Augusto Perazzolo Antoniazzi, Adrian Willig, Xiaobin Xing, Zhenyu Xu, Lucas Lourenço, Carlos Almeida Junior, Silvia Aparecida Teixeira, Rui Manuel Reis   +19 more
wiley   +1 more source

IDH1 R132C mutation is detected in clear cell hepatocellular carcinoma by pyrosequencing

World Journal of Surgical Oncology, 2017
Background Isocitrate dehydrogenase 1 (IDH1) mutation is common in low-grade glioma (approximately 80%) and acute myeloid leukemia (approximately 10%).
Jung Hee Lee, Dong Hoon Shin, Won Young Park, Nari Shin, Ahrong Kim, Hyun Jung Lee, Young Keum Kim, Kyung Un Choi, Jee Yeon Kim, Young Il Yang, Chang Hun Lee, Mee Young Sol   +11 more
doaj   +1 more source

IDH1 mutations in a Brazilian series of Glioblastoma [PDF]

Clinics, 2011
GBM may manifest rapidly de novo(primary GBM), or may develop slowly from grade II orgrade III astrocytomas (secondary GBM), suggesting thatthey are distinct disease entities that evolve throughdifferent genetic pathways.In recent genome-wide analyses, high rates of sponta-neous mutations in the gene encoding cytosolic NADP-dependent isocitrate ...
Uno, Miyuki, Oba-Shinjo, Sueli Mieko, Silva, Roseli da, Miura, Flavio, Clara, Carlos Afonso, Almeida, José Reynaldo Walther de, Malheiros, Suzana M. F, Bianco, André Macedo, Brandt, Reynaldo, Ribas, Guilherme Carvalhal, Feres, Halim, Dzik, Carlos, Rosemberg, Sérgio, Stavale, João Norberto, Teixeira, Manoel Jacobsen, Marie, Suely K. N   +15 more
openaire   +4 more sources

Metabolism‐Regulating Nanomedicines for Cancer Therapy

Advanced NanoBiomed Research, EarlyView.
This review highlights metabolism‐regulating nanomedicines designed to target glycolytic, lipid, amino acid, and nucleotide pathways in tumors. By incorporating metabolism‐regulating agents into versatile nanocarriers such as liposomes, micelles, dendrimers, and engineered bacteria, these platforms achieve targeted delivery, controlled release ...
Xiao Wu, Shiyi Geng, Jian Yang
wiley   +1 more source

IDH-1, ATRX AND 1P19Q CO-DELETION IN DIFFUSE GLIOMAS

Pakistan Armed Forces Medical Journal, 2020
Objective: To stratify diffuse gliomas into subtypes including diffuse astrocytomas, oligodendrogliomas and glioblastomas based on recent molecular updates and assess their frequencies in our local subpopulation. Study Design: Cross-sectional study.
Rabia Javed, Noreen Akhtar, Usman Hassan, Mohammad Azam, Asif Loya, Mudassir Hussain, Maryam Hameed, Sumera Butt, Sajid Mushtaq   +8 more
doaj  

IDH1 mutation impairs antiviral response and potentiates oncolytic virotherapy in glioma

Nature Communications, 2023
IDH1 mutations frequently occur early in human glioma. While IDH1 mutation has been shown to promote gliomagenesis via DNA and histone methylation, little is known regarding its regulation in antiviral immunity.
Xueqin Chen, Jun Liu, Yuqin Li, Yuequan Zeng, Fang Wang, Zexiong Cheng, Hao Duan, Guopeng Pan, Shangqi Yang, Yuling Chen, Qing Li, Xi Shen, Ying Li, Zixi Qin, Jiahong Chen, Youwei Huang, Xiangyu Wang, Yuli Lu, Minfeng Shu, Yubo Zhang, Guocai Wang, Kai Li, Xi Lin, Fan Xing, Haipeng Zhang   +24 more
doaj   +1 more source

Nanobiotechnology‐Based Approaches for Targeted Glioma Therapy

Advanced NanoBiomed Research, EarlyView.
Nanoparticle systems cross the blood–brain barrier to deliver drugs precisely to glioma cells. Lipid, polymeric, and magnetic carriers enable controlled release, tumor targeting, and microenvironment modulation. These nanoplatforms enhance chemotherapy, radiotherapy, and immunotherapy, improving therapeutic efficacy while reducing systemic toxicity ...
Jinwei Li, Yibo He, Yang Zhang, Lining Arnold Ju, Yao Wang, Jianxuan Zhou, Yinying Chai, Xuhui Hui, ShiYuan Tong, Si Zhang, Yanli Tan, Yinyan Wang   +11 more
wiley   +1 more source

Blood plasma lipid profile in glial tumors

Успехи молекулярной онкологии
Introduction. In glial tumors, lipid metabolism becomes abnormal. Analysis of lipid metabolism components can be an important characteristic of molecular and genetic profile of gliomas.Aim. To determine the correlation between plasma lipidome profile and
L. M. Obukhova, E. V. Balavina, T. A. Veselova, I. A. Medyanik, A. S. Grishin, V. F. Lazukin, M. M. Kontorshchikov   +6 more
doaj   +1 more source

IDH1 regulates the expression of interferon pathway-related gene IFIT3 [PDF]

Jichu yixue yu linchuang, 2021
Objective To explore the role of IDH1 in the expression of RNA binding proteins (RBPs) in glioma cell line LN229. Methods Lentivirus was used to construct IDH1 knockdown and control cells, and the expression of IDH1 was validated by RT-qPCR (real ...
TANG Wan-jun, PENG Xiao-zhong, HAN Wei
doaj